Orexo and ProStrakan Group have reconfigured the commercial rights to the product, Abstral, in various territories worldwide. Abstral is the novel, rapidly-disintegrating, sublingual (under the tongue) formulation of fentanyl, and an ...
Immunovaccine has reported a net loss of $1.7m for the third quarter ended 30 September 2012 compared to a net loss of $1.5m for the same quarter in 2011. According to the company the increased loss is due to the $155,000 increase in ...
Tags: Net Loss, therapeutic cancer vaccine, immune enhancement technology
The SFJ Pharmaceuticals Group (SFJ) has partnered with Pfizer to co-develop Dacomitinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal ...
Tags: Cancer Drug, cell lung cancer, therapy
DARA BioSciences has launched a liquid version of tamoxifen under the brand name Soltamox in the US Tamoxifen Citrate is the most common drug prescribed to treat breast cancer. Soltamox is expected to offer treatment option for patients ...
Tags: tamoxifen, Soltamox, breast cancer
DARA BioSciences has launched a liquid version of tamoxifen under the brand name Soltamox in the US. Tamoxifen Citrate is the most common drug prescribed to treat breast cancer. Soltamox is expected to offer treatment option for ...
Tags: DARA BioSciences, tamoxifen, Soltamox, Tamoxifen Citrate
Astellas Pharma's Gonax drug used in the treatment of prostate cancer, has been awarded marketing rights in Japan. Based on the positive results from phase I, II studies in Japan and phase III studies in abroad, Astellas has applied for ...
Advanced Cancer Therapeutics (ACT) has received Phase I small business innovative research (SBIR) grant of $158,000 from the National Cancer Institute of the National Institutes of Health (NIH) to support the development of an anti cancer ...
Tags: ACT, SBIR Grant, anti cancer drug, Anticancer Drug
Bedford Laboratories has issued a nationwide voluntary hospital/user-level recall of certain lots of leucovorin calcium injection due to the discovery of visible crystalline particulate matter in a small number of vials. The particulate ...
The European Commission (EC) has granted marketing authorization for Meda's Zyclara (imiquimod 3.75% cream) for the treatment of actinic keratosis (AK), in the European Union. Zyclara can detect and eliminate subclinical as well as ...
Tags: Meda Zyclara, actinic keratosis, clinical AK lesions, Skin cancer
Astellas Pharma has introduced Gonax (Degarelix Acetate), a gonadotrophin-releasing hormone (GnRH)-receptor blocker, for subcutaneous injection to treat prostate cancer in Japan. Gonax is designed to inhibit the binding of GnRH, a hormone ...
BioDelivery Sciences International (BDSI) has announced the introduction of Breakyl (fentanyl buccal film) in the European Union (EU) by Meda, its commercial partner for the product in the region. The launch triggered a $2.5m final EU ...
Celgene International Sàrl Abraxane, an albumin-bound form of paclitaxel, has demonstrated statistically significant improvementin overall survival for advanced pancreatic cancer patients in Phase III study. The Metastatic ...
ChiRhoClin has relaunched an orphan drug product,ChiRhoStim(Human Secretin for Injection)used to diagnose pancreatic cancer and pancreatic exocrine dysfunction. The company has received permission to market the current batch of ...
Tags: ChiRhoClin, Chirhostim Drug, orphan drug product, pancreatic cancer
VentiRx Pharmaceuticals has formed a world-wide collaboration with Celgene Corporation to develop VTX-2337, a highly potent and selective TLR8 agonist for cancer treatment. As part of the agreement, Celgene will fund $35m as upfront ...
Sagent Pharmaceuticals has introduced a folic acid derivative therapy, designed to treat megaloblastic anemias patients who are not responding to oral therapy. The new Leucovorin Calcium for Injection is indicated for rescue after ...